Article Details
Retrieved on: 2022-05-14 16:38:08
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
For the Phase II COAST study, the 3 arms evaluated the combination of durvalumab plus monalizumab and durvalumab plus oleclumab, AstraZeneca's anti- ...
Article found on: seekingalpha.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here